Published in J Infect Dis on August 15, 2007
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis (2011) 2.70
HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis (2009) 2.00
Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis (2009) 1.80
Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS (2010) 1.27
Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med (2011) 1.08
Treatment Options for HIV-Associated Tuberculosis. J Infect Dis (2007) 1.07
Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis (2010) 1.05
Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol (2010) 0.98
Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med (2010) 0.90
Disclosure of HIV status: Experiences of Patients Enrolled in an Integrated TB and HAART Pilot Programme in South Africa. Afr J AIDS Res (2009) 0.88
Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis (2012) 0.87
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest (2004) 3.69
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Intensive care of patients with HIV infection. N Engl J Med (2006) 2.86
The case for earlier treatment of HIV infection. Clin Infect Dis (2004) 2.20
The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis (2011) 2.20
Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health (2015) 2.10
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis (2007) 2.05
Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med (2007) 2.00
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2005) 2.00
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One (2012) 1.77
Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis (2002) 1.74
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis (2008) 1.66
Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol (2012) 1.44
Regulation of tumor necrosis factor alpha gene expression by mycobacteria involves the assembly of a unique enhanceosome dependent on the coactivator proteins CBP/p300. Mol Cell Biol (2003) 1.42
The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis (2013) 1.39
Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol (2005) 1.37
Transcriptional control of the TNF gene. Curr Dir Autoimmun (2010) 1.32
Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci U S A (2002) 1.31
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2012) 1.26
Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis (2012) 1.26
T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev (2015) 1.26
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc (2012) 1.21
Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.21
Inducer-specific enhanceosome formation controls tumor necrosis factor alpha gene expression in T lymphocytes. Mol Cell Biol (2002) 1.20
Activation-dependent intrachromosomal interactions formed by the TNF gene promoter and two distal enhancers. Proc Natl Acad Sci U S A (2007) 1.18
HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS (2010) 1.16
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr (2014) 1.14
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis (2013) 1.11
"A bird in the hand...": a commentary on the test and treat approach for HIV. Arch Intern Med (2010) 1.08
NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone. Nucleic Acids Res (2005) 1.06
The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting. Clin Infect Dis (2012) 1.06
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med (2010) 1.05
Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression. J Biol Chem (2007) 1.05
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr (2013) 1.05
Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis (2010) 1.05
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother (2012) 1.04
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr (2011) 1.04
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One (2010) 0.99
Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis (2011) 0.99
NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site. PLoS Pathog (2006) 0.99
High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/μL under routine program conditions in Uganda. Clin Infect Dis (2013) 0.98
Aspartic acid homozygosity at codon 57 of HLA-DQ beta is associated with susceptibility to pulmonary tuberculosis in Cambodia. J Immunol (2006) 0.98
A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS (2014) 0.98
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS (2015) 0.97
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol (2014) 0.95
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS (2014) 0.95
Transactivator of transcription from HIV type 1 subtype E selectively inhibits TNF gene expression via interference with chromatin remodeling of the TNF locus. J Immunol (2006) 0.94
HIV-1 replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS One (2009) 0.94
Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. Adv Immunol (2013) 0.94
Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS (2015) 0.94
Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat. Am J Respir Cell Mol Biol (2011) 0.93
Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr (2014) 0.92
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther (2010) 0.92
Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med (2002) 0.92
Primate TNF promoters reveal markers of phylogeny and evolution of innate immunity. PLoS One (2007) 0.92
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol (2004) 0.92
Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis. Clin Infect Dis (2009) 0.91
A dimer-specific function of the transcription factor NFATp. Proc Natl Acad Sci U S A (2008) 0.91
Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health (2014) 0.91
Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS (2007) 0.91
HIV integrase inhibitors--out of the pipeline and into the clinic. N Engl J Med (2008) 0.90
Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog (2012) 0.89
Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes. J Virol Methods (2010) 0.89
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS (2002) 0.89
Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods (2011) 0.88
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis (2006) 0.88
T cell-specific expression of the human TNF-alpha gene involves a functional and highly conserved chromatin signature in intron 3. J Immunol (2003) 0.88
Complications of HIV disease and antiretroviral therapy. Top HIV Med (2009) 0.88
Overcoming the human immunodeficiency virus obstacle course. JAMA Intern Med (2013) 0.87
Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.87
Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis (2010) 0.87
Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 0.86
Defective interleukin-2-dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS (2004) 0.86
Mycobacterium tuberculosis recall antigens suppress HIV-1 replication in anergic donor cells via CD8+ T cell expansion and increased IL-10 levels. J Immunol (2004) 0.86
The use of HaloTag-based technology in flow and laser scanning cytometry analysis of live and fixed cells. BMC Res Notes (2011) 0.85
Mortality among antiretroviral-eligible patients in an urban public clinic. J Acquir Immune Defic Syndr (2011) 0.85
HIV RNA suppression among HIV-infected Ugandan children with measles. J Acquir Immune Defic Syndr (2008) 0.85
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials (2007) 0.85
Antiretroviral therapy and TB. Trop Doct (2006) 0.84
High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS (2016) 0.84
Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS (2016) 0.84
Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr (2016) 0.83